Jenna Ventorino


Ventorino, Jenna

Jenna Ventorino is an up-and-coming corporate lawyer who provides ongoing counsel to public and private technology and life sciences companies. She advises clients in the biotechnology, software, telecommunications and clean technology industries in complex transactions including mergers and acquisitions, intellectual property licensing and private securities offerings. She draws on her prior experience as in-house counsel to help her clients navigate their legal and business challenges.

In addition to advising clients on a wide range of corporate and securities matters, Ms. Ventorino advises clients on various licensing transactions including joint venture arrangements, strategic alliances and other collaboration deals. She negotiates on collaboration, development, distribution, license and service agreements with customers, suppliers, licensors, licensees and other third parties, and on the acquisition and sale of intellectual property or other technology.

Ms. Ventorino counsels emerging companies throughout their lifecycle and in venture capital financings and exit transactions. She also has experience representing private and institutional investors in private investments and related transactions.


Prior to joining the firm, Ms. Ventorino worked as an associate at a business law firm where she negotiated mergers, acquisitions, divestitures and other strategic transactions; drafted agreements related to software and patent licensing; provided IP consulting services; and advised on IP-centered strategic transactions and joint ventures. Ms. Ventorino also worked with private companies, venture capital firms and other investors to structure and negotiate debt and equity financings.

Ms. Ventorino previously worked as an attorney for Kenexa Technology, Inc. (formerly, Inc.), where she managed the compensation division.

Recent Highlights

Ms. Ventorino represents private companies in various stages of development, publicly traded companies, and investment firms that have a particular focus on tech and life sciences. She has represented:

  • Aileron Therapeutics, Inc. in its initial public offering;
  • Affirmed Networks, Inc. in its acquisition of Hitachi Communication Technologies America, Inc.;
  • American Express in participating agreements for AndroidPay and SamsungPay;
  • Editas Medicine in its strategic alliance and option agreement with Allergan;
  • Spark Therapeutics in its synthetic vaccine particles licensing transaction with Selecta Biosciences, and in its licensing agreement with Novartis Pharmaceuticals to develop and commercialize investigational voretigene neparvovec outside the United States;
  • numerous companies in venture capital and private financings, including Aileron Therapeutics, Daktari Diagnostics, Jebbit, Nantero and RightHand Robotics; and
  • venture capital firms including MPM Capital and Spark Capital in various private placement financings and strategic investments.

Professional Activities

Ms. Ventorino is an active member of WilmerHale's Women's Leadership Initiative and leads the east coast's Female Founders initiative—an effort that brings awareness to the issues facing leaders and executives from women-led startup businesses.

In addition, she is a member of the Boston Bar Association, Women's Bar Association, the Cornell University Alumni Ambassador Association and an alumni mentor for the Boston University School of Law. She is a former board member of the Cornell University Human Ecology Alumni Association.

Honors & Awards

  • Named a 2017 Massachusetts Rising Star by Super Lawyers for her business/corporate and technology transactions practices
  • Selected to participate in the 2015-2016 Women's Bar Association Women's Leadership Initiative

Publications & News


May 22, 2018

WilmerHale Counsels Accent Therapeutics in $40M Series A Financing

On May 18, 2018, Accent Therapeutics, a biopharmaceutical company developing breakthrough treatments for cancer patients, announced its $40M Series A financing to establish a discovery platform and pipeline of therapeutic candidates targeting RNA-modifying proteins.

May 8, 2018

WilmerHale Counsels Nantero in $29.7M Series G Funding

Nantero Inc., a nanotechnology company developing next generation memory using carbon nanotubes, announced that it has expanded product development with a wide range of new and existing customers.

January 26, 2018

WilmerHale Represents Spark Therapeutics in Licensing and Supply Agreement With Novartis

Spark Therapeutics, a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced it has entered into a licensing agreement with Novartis Pharmaceuticals to develop and commercialize investigational voretigene neparvovec outside the United States.

November 6, 2017

WilmerHale Represents 1366 Technologies in $9M Series D Funding

Developer of manufacturing solutions for silicon cell manufacturers, 1366 Technologies, has raised $9 million in Series D funding from strategic partners and return investors.

October 26, 2017

WilmerHale Reps MacroGenics in Global Collaboration and Licensing Agreement With Incyte

MacroGenics, Inc. and Incyte Corporation announced that they have entered into an exclusive global collaboration and license agreement for MacroGenics' MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1).

August 10, 2017

WilmerHale Represents Jebbit in Raising $6.8M Series A Investment

Jebbit, a Boston-based venture-backed startup that has built the world's first declared data platform, announced that it closed a $6.8 million Series A round to continue growing its declared data platform for enterprise companies.

July 6, 2017

WilmerHale Represents Aileron Therapeutics in IPO

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a novel class of therapeutics called stapled peptides for cancers and other diseases, announced the pricing of its initial public offering.

April 10, 2017

WilmerHale Counsels RightHand Robotics in Raising $8M in Equity Financing

RightHand Robotics, a leader in providing end-to-end solutions that reduce the cost of e-commerce order-fulfillment of industries including electronics, apparel, grocery and pharmaceuticals, announced it has raised $8 million in equity financing.

March 16, 2017

Allergan and Editas Medicine Enter Into Strategic R&D Alliance

The agreement covers early stage, first-in-class ocular programs targeting serious diseases based on Editas Medicine's unparalleled CRISPR genome editing platform.

December 15, 2016

WilmerHale Reps Spark Therapeutics in Licensing Agreement with Selecta Biosciences

Spark Therapeutics and Selecta Biosciences, Inc. announced a license agreement that provides Spark Therapeutics with exclusive worldwide rights to Selecta's proprietary Synthetic Vaccine Particles platform technology for co-administration with gene therapy targets.


Skip Navigation Links.


JD, cum laude, Boston University School of Law, 2008, Editor, American Journal of Law and Medicine

MS, Family, Nutrition and Exercise Science, Queens College, City University of New York, 2004

BS, Nutritional Science, Cornell University, 1999, Phi Eta Sigma National Honor Society

Bar Admissions


New York

Skip Navigation Links.